A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.

Lin CaiCongjun JiangGuoqiang ZhangHong FangJinyan WangYumei LiHui XuRong XiaoYangfeng DingKun HuangChunlei ZhangLitao ZhangBin ChenXinsuo DuanWeili PanGuangming HanRongyi ChenLunfei LiuShoumin ZhangJuan TaoXiaowen PangJianbin YuHuiping WangYi ZhaoChengxin LiXiaojing KangLanying QinXiaofang ZhuJuan SuShanshan LiChunjun YangWenli FengTiechi LeiShan JiangRuihua FangMao LinQianjin LuChunxing XuWei WangJianzhong Zhang

Published in: The British journal of dermatology (2024)

Xeligekimab showed high efficacy and is well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.

Keyphrases

placebo controlled
double blind
clinical trial
phase iii
phase ii
open label
coronary artery disease
high intensity
early onset
study protocol
phase ii study
drug induced
atopic dermatitis
radiation therapy
cross sectional
hidradenitis suppurativa